184 related articles for article (PubMed ID: 33859303)
1. Sarcoma IL-12 overexpression facilitates NK cell immunomodulation.
Rademacher MJ; Cruz A; Faber M; Oldham RAA; Wang D; Medin JA; Schloemer NJ
Sci Rep; 2021 Apr; 11(1):8321. PubMed ID: 33859303
[TBL] [Abstract][Full Text] [Related]
2. Fate control engagement augments NK cell responses in LV/hu-IL-12 transduced sarcoma.
Rademacher MJ; Faber ML; Bone KM; Medin JA; Schloemer NJ
Exp Mol Pathol; 2024 May; 137():104898. PubMed ID: 38729059
[TBL] [Abstract][Full Text] [Related]
3. Enhanced development of functional human NK cells in NOD-scid-IL2rg
Aryee KE; Burzenski LM; Yao LC; Keck JG; Greiner DL; Shultz LD; Brehm MA
FASEB J; 2022 Sep; 36(9):e22476. PubMed ID: 35959876
[TBL] [Abstract][Full Text] [Related]
4. Human Hematopoietic Stem Cell Engrafted IL-15 Transgenic NSG Mice Support Robust NK Cell Responses and Sustained HIV-1 Infection.
Abeynaike SA; Huynh TR; Mehmood A; Kim T; Frank K; Gao K; Zalfa C; Gandarilla A; Shultz L; Paust S
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851579
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12 gene modification exerts anti-tumor effects on murine mammary sarcoma cell line in vivo.
Li D; Yu H; Xu TF; Li JH; Sun YF; Zhang WQ
Cell Mol Immunol; 2008 Jun; 5(3):225-30. PubMed ID: 18582405
[TBL] [Abstract][Full Text] [Related]
6. Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse.
Katano I; Takahashi T; Ito R; Kamisako T; Mizusawa T; Ka Y; Ogura T; Suemizu H; Kawakami Y; Ito M
J Immunol; 2015 Apr; 194(7):3513-25. PubMed ID: 25712215
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.
Seay K; Church C; Zheng JH; Deneroff K; Ochsenbauer C; Kappes JC; Liu B; Jeng EK; Wong HC; Goldstein H
J Virol; 2015 Jun; 89(12):6264-74. PubMed ID: 25833053
[TBL] [Abstract][Full Text] [Related]
8. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
9. CD8 T cells in innate immune responses: using STAT4-dependent but antigen-independent pathways to gamma interferon during viral infection.
Suarez-Ramirez JE; Tarrio ML; Kim K; Demers DA; Biron CA
mBio; 2014 Oct; 5(5):e01978-14. PubMed ID: 25336459
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro.
Ahmed Ali HA; Di J; Mei W; Zhang YC; Li Y; Du ZW; Zhang GZ
Asian Pac J Cancer Prev; 2014; 15(2):611-6. PubMed ID: 24568466
[TBL] [Abstract][Full Text] [Related]
11. Differences in Tumor Growth and Differentiation in NSG and Humanized-BLT Mice; Analysis of Human vs. Humanized-BLT-Derived NK Expansion and Functions.
Kaur K; Jewett A
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612108
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunoediting by the innate immune system in the absence of adaptive immunity.
O'Sullivan T; Saddawi-Konefka R; Vermi W; Koebel CM; Arthur C; White JM; Uppaluri R; Andrews DM; Ngiow SF; Teng MW; Smyth MJ; Schreiber RD; Bui JD
J Exp Med; 2012 Sep; 209(10):1869-82. PubMed ID: 22927549
[TBL] [Abstract][Full Text] [Related]
13. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
14. Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.
Moran JP; Gerber SA; Martin CA; Frelinger JG; Lord EM
Int J Cancer; 2003 Sep; 106(5):690-8. PubMed ID: 12866028
[TBL] [Abstract][Full Text] [Related]
15. IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells.
Kannan Y; Yu J; Raices RM; Seshadri S; Wei M; Caligiuri MA; Wewers MD
Blood; 2011 Mar; 117(10):2855-63. PubMed ID: 21224476
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
17. IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation.
Lusty E; Poznanski SM; Kwofie K; Mandur TS; Lee DA; Richards CD; Ashkar AA
Mol Immunol; 2017 Aug; 88():138-147. PubMed ID: 28644973
[TBL] [Abstract][Full Text] [Related]
18. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO.
Chanswangphuwana C; Allan DSJ; Chakraborty M; Reger RN; Childs RW
Mol Ther; 2021 Jan; 29(1):47-59. PubMed ID: 33010232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
